NCT02801435View on ClinicalTrials.gov

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 17, 2016

Primary Completion Date

June 8, 2017

Study Completion Date

June 8, 2017

Conditions
Psoriasis
Interventions
DRUG

0.5% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

1.0% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

2.0% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

4.0% Icotinib hydrochloride cream

Topical administration for twice daily

DRUG

Placebo

Topical administration for twice daily

Trial Locations (1)

310009

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT02801435 - Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis | Biotech Hunter | Biotech Hunter